This Article Full Text Full Text (PDF) All Versions of this Article: 147/11/5333    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Husen, B. Articles by Poutanen, M. Search for Related Content PubMed PubMed Citation Articles by Husen, B. Articles by Poutanen, M.

Human Hydroxysteroid (17-ß) Dehydrogenase 1 Expression Enhances Estrogen Sensitivity of MCF-7 Breast Cancer Cell Xenografts

Solvay Pharmaceuticals Research Laboratories (B.H., J.M., H.H.T.), 30173 Hannover, Germany; and Department of Physiology (K.H., T.S., M.P.), Institute of Biomedicine, University of Turku, 20520 Turku, Finland

Address all correspondence and requests for reprints to: Bettina Husen, Solvay Pharmaceuticals Research Laboratories, Hans-Böckler-Allee 20, 30173 Hannover, Germany. E-mail: bettina.husen{at}solvay.com.

Hydroxysteroid (17-ß) dehydrogenase 1 (HSD17B1) catalyzes the conversion between estrone (E1) and estradiol (E2). The reaction is reversible in vitro, but the data in cultured cells suggest that E2 production is the predominant reaction in physiological conditions. However, the hypothesis has not been verified in vivo. In the present study, estrogen-dependent MCF-7 human breast cancer cells were stably transfected with an expression plasmid for human HSD17B1. The enzyme efficiently converted E1 to E2 and enhanced the estrogen-dependent growth of cultured MCF-7 cells in the presence of hormonally less active E1. The HSD17B1-expressing cells also formed estrogen-dependent tumors in immunodeficient nude mice. After treating the mice with an appropriate dose of the substrate (E1, 0.1 µmol/kg·d), a marked difference in tumor growth was observed between nontransfected and HSD17B1-transfected MCF-7 cells, mean tumor weights at the end of E1 treatment being 23.2 and 130.4 mg, respectively. Furthermore, estrogen-dependent growth of the HSD17B1-expressing xenografts in the presence of E1 was markedly inhibited by administering 5 µmol/kg·d of a specific HSD17B1 inhibitor. After a 4-wk treatment, the tumor size was reduced by 59.8% as compared with the nontreated tumors, whereas the uterine growth of the mice was not affected by the HSD17B1 inhibitor used. This was in line with the induction of apoptosis of the tumors. The results evidently show that estrogenic response for E1 is enhanced by the local action of HSD17B1 in vivo, and thus, the enzyme is a potential target for pharmacological inhibition of estrogen action.

This article has been cited by other articles:

				H. Dassen, C. Punyadeera, R. Kamps, B. Delvoux, A. Van Langendonckt, J. Donnez, B. Husen, H. Thole, G. Dunselman, and P. Groothuis Estrogen metabolizing enzymes in endometrium and endometriosis Hum. Reprod., December 1, 2007; 22(12): 3148 - 3158. [Abstract] [Full Text] [PDF]

				T. Saloniemi, T. Lamminen, K. Huhtinen, M. Welsh, P. Saunders, H. Kujari, and M. Poutanen Activation of Androgens by Hydroxysteroid (17{beta}) Dehydrogenase 1 in Vivo as a Cause of Prenatal Masculinization and Ovarian Benign Serous Cystadenomas Mol. Endocrinol., November 1, 2007; 21(11): 2627 - 2636. [Abstract] [Full Text] [PDF]